NCR Online Journal

20+ Leading Dengue Pipeline Companies are working to improve the Treatment Landscape

 Breaking News
  • No posts were found

20+ Leading Dengue Pipeline Companies are working to improve the Treatment Landscape

February 07
23:53 2023
20+ Leading Dengue Pipeline Companies are working to improve the Treatment Landscape

DelveInsight’s, “Dengue Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the Dengue pipeline drug profiles, including Dengue clinical trials and nonclinical stage products. It also covers the Dengue pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Dengue Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Dengue NDA approvals (if any), and product development activities comprising the technology, Dengue collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Dengue Pipeline Insight Report

 

  • DelveInsight’s Dengue pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Dengue treatment.

 

  • The leading Dengue Companies includes Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.

 

  • Promising Dengue Pipeline Therapies includes Dengushield 1 mg/kg (Cohort 1) intravenous, HD vehicle-GNP, Tetravalent Dengue Vaccine (TDV), 9vHPV vaccine, Dengue Tetravalent Vaccine (TDV), Takeda’s Tetravalent Dengue Vaccine Candidate (TDV), and others.

 

  • The Dengue companies and academics are working to assess challenges and seek opportunities that could influence Dengue R&D. The Dengue pipeline therapies under development are focused on novel approaches to treat/improve Dengue.

 

To explore more information on the latest breakthroughs in the Dengue Pipeline treatment landscape of the report, click here @ Dengue Pipeline Outlook

 

Dengue Overview

Dengue is a mosquito-transmitted virus and the leading cause of arthropod-borne viral disease in the world. It is also known as breakbone fever due to the severity of muscle spasms and joint pain, dandy fever, or seven-day fever because of the usual duration of symptoms. Although most cases are asymptomatic, severe illness and death may occur. Aedes mosquitoes transmit the virus and are common in tropical and subtropical parts of the world.

 

Dengue Emerging Drugs Profile 

 

VIS 513: Visterra

VIS513, is a monoclonal antibody in development for the treatment of Dengue, a serious mosquito-borne virus, which in its most severe forms is characterized by uncontrolled bleeding leading to organ failure and death. VIS513 has in vitro and in vivo activity against all four Dengue virus serotypes found globally.

 

TAK-003: Takeda

Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses. Clinical Phase II data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants, which persisted through 48 months after vaccination, and the vaccine was found to be generally safe and well tolerated. The pivotal Phase 3 TIDES trial met its primary endpoint of overall vaccine efficacy (VE) against virologically confirmed dengue (VCD) at 12 months follow-up and all secondary endpoints at 18 months follow-up for which there were a sufficient number of dengue cases, including VE against hospitalized dengue and VE in baseline seropositive and baseline seronegative individuals. The results demonstrated TAK-003 was generally well tolerated, and there have been no important safety risks observed to date.Takeda announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the prevention of dengue due to any dengue virus serotype in individuals ages four to 60.

 

CDX DENV: Codagenix

Codagenix has leveraged the platform to re-design contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates. CDX DENV, is a Synthetic vaccine being developed in the Pre-Clinical stage for the treatment of Dengue.

 

AT 752: Atea Pharmaceuticals

AT-752, a diastomer of AT-527, is a novel purine nucleotide prodrug, designed to treat patients either newly infected or previously infected with the dengue virus. AT-752 has an favorable preclinical safety profile and has demonstrated potent in vitro activity against all dengue serotypes tested as well as potent antiviral activity in predictive animal models. Atea Pharmaceuticals plan to conduct clinical studies that will evaluate the daily administration of AT-752 over a short period of treatment, in order to negate the progression of infection and reduce the occurrence of life-threatening conditions associated with severe dengue.

 

For further information, refer to the detailed Dengue Unmet Needs, Dengue Market Drivers, and Dengue Market Barriers, click here for Dengue Ongoing Clinical Trial Analysis

 

Dengue Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Dengue. The companies which have their Dengue drug candidates in the most advanced stage, i.e. Pre-Regisration include, Takeda.

 

Dengue Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Request a sample and discover the recent advances in Dengue Ongoing Clinical Trial Analysis and Medications, click here @ Dengue Treatment Landscape

 

Scope of the Dengue Pipeline Report

 

  • Coverage- Global

 

  • DengueCompaniesVisterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others

 

  • Dengue Pipeline Therapies- Dengushield 1 mg/kg (Cohort 1) intravenous, HD vehicle-GNP, Tetravalent Dengue Vaccine (TDV), 9vHPV vaccine, Dengue Tetravalent Vaccine (TDV), Takeda’s Tetravalent Dengue Vaccine Candidate (TDV), and others.
  • Dengue Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Route of Administration

 

Dive deep into rich insights for drugs for Dengue Market Drivers and Dengue Market Barriers, click here @ Dengue Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Dengue: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Dengue– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. TAK-003: Takeda
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug Name: Company Name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AT 752: Atea Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Dengue Key Companies
  21. Dengue Key Products
  22. Dengue- Unmet Needs
  23. Dengue- Market Drivers and Barriers
  24. Dengue- Future Perspectives and Conclusion
  25. Dengue Analyst Views
  26. Dengue Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Dengue Mergers and acquisitions, Dengue Licensing Activities @ Dengue Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services